The Samsung brand is best known for its smartphones and wide-screen TVs. Yet behind the scenes, the conglomerate is also making a name as a contract manufacturer of complex medicines to treat diseases such as cancer.
On a piece of reclaimed land along South Korea’s western coast, Samsung BioLogics Co is building a US$740 million factory that is to give it the capacity to become the No. 1 producer by volume of a class of drugs called biologics, many of which are derived from mammal cells.
The Samsung group diversified into the pharmaceutical sector in 2011. Now, it is mobilizing its expertise in semiconductor making and engineering to make the way biologics are produced more efficient.
The market for biologic medicines, which are used for everything from cancer to arthritis, is projected to exceed US$223.7 billion by 2021, according to a Bloomberg Intelligence analysis.
Being a force in biologics is crucial to Samsung — and South Korea. Galaxy smartphones and other consumer electronics face intense competition from Apple Inc and Chinese brands such as Huawei Technologies Co (華為), and Samsung is grappling with the arrest of de facto leader Jay Y. Lee in a scandal that brought down former South Korean president Park Geun-hye. Meanwhile, the broader economy needs new industries as shipbuilding and heavy manufacturing slow.
If the past 40 years of global economic growth were fueled by technology, the next are to be fueled by where that converges with healthcare, Samsung BioLogics chief executive officer Kim Tae-han said.
In an interview at company headquarters in Incheon, Kim said he is preparing to ramp up production and is in negotiations for more than 15 new contracts.
The Samsung board gave him the green light and US$2 billion to start the business about six years ago, he said.
However, on the strength of demand and business performance, “I’ve already spent US$3 billion,’’ he said.
Sales totaled 107.6 billion won (US$96.36 million) in the first quarter, a 2.1 percent year-on-year increase, although the unit still posted a net loss.
More than 2,000 construction workers — most with experience building semiconductor facilities — are buzzing around the factory site about an hour’s drive from Seoul. It is called Edison and is the company’s third drug facility. Its five floors encompass 34m, making way for custom-made vats that are so big some shoot through several floors.
Biologic drugs are grown from cells. That necessitates a more complex manufacturing process than typical pills — a mixture of chemicals — but makes biologics more effective and capable of being targeted toward certain diseases.
Building a biologic plant is similar to building one for semiconductors. There are clean rooms that cannot tolerate dust or other contamination, so Edison is being built without nuts or bolts to prevent any drilling. Everything is welded and tilted to fit together.
One day, “contract manufacturing” could extend to helping clients build the factories, Kim said.
‘ACCORDING TO PLAN’: A company official said that it has set up production sites worldwide to provide services and that its Wisconsin project was going smoothly Hon Hai Precision Industry Co’s (鴻海精密) smart manufacturing center in Wisconsin would begin trial manufacturing in the middle of this year, the company said yesterday, adding that it plans to build a research institute to develop key technologies to support growth over the next five years. Hon Hai, known internationally as Foxconn Technology Group (富士康科技集團), said in an annual report submitted to the Taiwan Stock Exchange that its planned Foxconn Institute for Research in Science and Technology would conduct research into artificial intelligence, next-generation communications, quantum computing, cybersecurity and nano semiconductors in Taiwan. Hon Hai is to make products at the center
TV and online retailer Momo.com Inc (富邦媒體) yesterday said it has set up a new logistics subsidiary, Fu Sheng Logistics Co (富昇物流), to oversee the company’s extensive shipping operations. Leveraging Momo’s 23 satellite warehouses and distribution centers nationwide, Fu Sheng will be in charge of executing the retailer’s same-day shipment plan for deliveries in Taipei, New Taipei City, Taoyuan, Taichung, Tainan and Kaohsiung, Momo said in a press release. Seeking to further shorten its supply chain, the company is to set up another seven satellite warehouses and distribution centers by the end of the year. “Fu Sheng has a fleet of 200 couriers
STAYING AHEAD: Fitch said that TSMC remains technologically ahead of others, but Samsung is building a new chip fab, while China is investing in its domestic industry As escalating US-China tensions and COVID-19-related production disruptions force US technology supply chains to transform, Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$12 billion chip fabrication plant in Arizona would be key to spurring greater US production of core semiconductor components, Fitch Ratings said. “We view the US-TSMC alliance as a first step in building a more autonomous US technology supply chain, given high barriers to entry, specifically related to the significant capital and design capability required for leading-edge semiconductor manufacturing,” Fitch said in a statement on Tuesday. “By working with TSMC, US chipmakers will not face the financial burden of incremental investment
E Ink Holdings Inc (元太科技), the world’s sole supplier of e-paper displays for e-readers and shelf labels, posted its best quarterly net profit for the first quarter in nine years amid increased demand during a traditionally slow season. Net profit soared 80 percent to NT$787 million (US$26.23 million) in the quarter ended March 31, compared with NT$438 million a year earlier. That translated into earnings per share of NT$0.69, up from NT$0.39. E Ink posted lower royalty income of NT$371.23 million last quarter from NT$448.74 million a year earlier, a company financial statement showed. E Ink said that it expects royalty income to